Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine Transdermal System Extension in OA Pain
NCT01141283Phase 3Completed
- Sponsor
- Purdue Pharma
- Start
- Apr 2003
- Primary completion
- Jul 2004
- Modality
- Orthosteric Ligands, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of v1003 in osteoarthritis (OA), sponsored by Purdue Pharma. Primary endpoint: Number of Participants With Adverse Events at 6 months. Started Apr 2003; status: completed.
02
Drugs
v1003
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT01141283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01141283.